A lesion’s contrast enhancement pattern and change in size after treatment can predict the successful radio-frequency ablation of a lung tumor, according to a study in the October issue of the American Journal of Roentgenology.
A lesion's contrast enhancement pattern and change in size after treatment can predict the successful radio-frequency ablation of a lung tumor, according to a study in the October issue of the American Journal of Roentgenology.
Dr. Gong Yong Jin and colleagues at Chonbuk and Seoul National University Hospitals in Korea retrospectively evaluated 21 patients who underwent percutaneous RFA for lung cancer and metastases from extrapulmonary lesions. Using contrast-enhanced CT, they sought to describe postablation lesion characteristics and patient response to treatment.
The researchers found that the most successfully ablated lesions appeared on follow-up scans as low-attenuation areas without contrast enhancement. These lesions consistently shrank on subsequent follow-up scans.
Based on contrast-enhanced CT findings after treatment, the researchers split patients into two groups: those who had achieved complete ablation, and those with a partial ablation. Follow-up CT imaging of each group showed serial changes in enhancement patterns, size, peripheral ground-glass opacities, and other factors.
Nine patients in the complete ablation group showed no contrast enhancement on follow-up CT. Their lesions' mean reduction rate at three, six, nine, 12, and 15 months compared with the size right after treatment was 5.7%, 11.4%, 14.3%, 40%, and 40%, respectively.
Twelve patients in the partial ablation group showed diverse degrees of enhancement. In contrast to the previous group, their lesions gradually increased in size after the six-month follow-up with CT. Five out of 21 lesions on postablation scans showed enveloped ground-glass opacity surrounding the tumor.
Usually, a brief increase in blood flow occurs along the tissue surrounding an ablated lesion. Experts speculate that residual malignant cells overlapping this area might go undetected by follow-up CT immediately after treatment. Ablation should thus include a peripheral normal tissue margin of .5 to 1 cm to boost results and increase the sensitivity of treatment follow-up.
Lack of histopathologic confirmation limited the study's measure for success. Several other researchers, however, agree that contrast-enhanced CT findings may correlate well with the ablated lesion's pathologic features, the investigators wrote in the study.
For more information from the Diagnostic Imaging archives:
RFA for liver breaks further ground
RF ablation of lung tumors wins support
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.